Company / PP&E (Net)
Kura Oncology, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$7.9M
FY2025
5-year range
$1.7M / $7.9M
FY2021-FY2025
Trend
+367.0%
vs FY2024
Sector context
#100 of 193
Health Care
What the data says
PP&E (Net) changed +367% YoY in FY2025, a notable deviation from the 8-year average annual change of +640%.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of +31.2%.
Improved from $2M to $8M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +45.7%
- 5-Year CAGR
- +31.2%
- 10-Year CAGR
- -
Sector benchmark
#100 of 193 in Health CareTop 52% of 193This company $7.9M Sector average $777.6M
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +31.2%, indicating consistent growth.
- In FY2025, pp&e (net) increased 367.0% year-over-year.
- Ranks #100 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.9M | +367.0% |
| FY2024 | $1.7M | -9.5% |
| FY2023 | $1.9M | -26.8% |
| FY2022 | $2.5M | -5.0% |
| FY2021 | $2.7M | +32.3% |
| FY2020 | $2.0M | +4493.2% |
| FY2019 | $44.0K | - |
| FY2018 | - | - |
| FY2017 | $10.0K | -75.0% |
| FY2016 | $40.0K | -43.7% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026